For decades, Eve Baer remained convinced that her son, unresponsive after a severe brain injury, was still conscious. Science ...

We believe Vertex is in strong financial health, given its robust cash flow generation and low debt. At the end of 2024, Vertex held about $11.2 billion in cash and equivalents.

Vertex Pharmaceuticals remains on hold with a $494 price target from Stifel analysts after discussions about its chronic pain ...

The Invesco Health Care Fund underperformed its benchmark for the first quarter of 2025. Click here to read the full ...

CRISPR Therapeutics partnered with big biotech Vertex Pharmaceuticals ( VRTX 3.40%) on Casgevy. Although Vertex takes a ...

Vertex Pharmaceuticals' shares dropped due to poor first-quarter results. Vertex's business and prospects remain attractive.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals is diversifying its already strong lineup of medicines. Axsome Therapeutics has multiple clinical and ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...